State of Nordic
Biopharma
1 January – 31 March 2026
A quarter defined by Novo Nordisk's turbulence
Q1 2026 was shaped by CagriSema's failed head-to-head trial, a bearish outlook from Novo Nordisk, and back-to-back FDA approvals of Wegovy HD and Awiqli. Small-cap Nordic biotech faced continued funding pressure, with multiple rights issues and one company entering dissolution. Meanwhile, AI adoption accelerated structurally across the sector.
15 pages of Nordic biopharma intelligence
Executive Summary
Quarter-defining events, top 5 data points, and sentiment snapshot.
Market Performance
Three-index dashboard, SVG chart, and 10 top movers (5 gainers, 5 decliners) with verified Q1 returns.
Top Events & Catalysts
Large-cap and mid/small-cap events ranked by materiality, with source references.
Sector Themes
GLP-1 dominance, funding pressure, AI integration, and earnings signals.
Capital Markets
Equity financings, M&A and partnerships, wind-downs. Who raised, at what terms.
Catalyst Watch
15 binary, asymmetric, and incremental catalysts mapped across Q2–Q4 2026.
Investor Insights
Six themes for the road ahead: financing strain, valuation reset, PDUFA calendar, AI, M&A, and Novo.
Sources
49 referenced press releases with clickable URLs. Sourced from MFN, Cision, and GlobeNewswire.
Know what moved – and what moves next
Understand where Nordic biopharma is heading – and which companies could re-price next.
- Which Novo Nordisk catalyst could set the floor – or extend the downturn
- Five PDUFA dates with binary stock-moving potential in Q2–Q3
- The funding crisis separating survivors from wind-downs
- Why Big Pharma's patent cliff makes Nordic assets attractive targets
- The quarter’s biggest winners and losers – from +438% to –87%, with driver commentary
Get instant access to the full State of Nordic Biopharma report
15 pages. 49 referenced sources. Free.
By downloading you agree to receive future BioStock Analytics reports. Unsubscribe anytime. We don't share your data.
